Pierre Peterlin

Nantes, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 148 publications

Olutasidenib Alone or in Combination With Azacitidine as a Bridge to Transplant in Relapsed/Refractory mIDH1 AML.

Olutasidenib Alone or in Combination With Azacitidine as a Bridge to Transplant in Relapsed/Refractory mIDH1 AML.

Journal: European journal of haematology

Published: May 27, 2026

Treosulfan or busulfan plus clofarabine as reduced intensity conditioning regimen before allotransplant for adults with myeloid malignancies.

Treosulfan or busulfan plus clofarabine as reduced intensity conditioning regimen before allotransplant for adults with myeloid malignancies.

Journal: Bone marrow transplantation

Published: May 19, 2026

Relationship Between Salvage Strategy and Outcomes in Patients With CBF or NPM1-mutated AML and First Molecular Relapse.

Relationship Between Salvage Strategy and Outcomes in Patients With CBF or NPM1-mutated AML and First Molecular Relapse.

Journal: Blood advances

Published: May 13, 2026

Ivosidenib monotherapy in IDH1 mutated myelodysplastic neoplasm/syndrome.

Ivosidenib monotherapy in IDH1 mutated myelodysplastic neoplasm/syndrome.

Journal: Leukemia

Published: April 12, 2026

Prognostic impact of FLT3-ITD microclones in young adults with acute myeloid leukemia treated with intensive chemotherapy.

Prognostic impact of FLT3-ITD microclones in young adults with acute myeloid leukemia treated with intensive chemotherapy.

Journal: Blood

Published: January 20, 2026

Prognostic impact of FLT3-ITD microclones in young adults with acute myeloid leukemia treated with intensive chemotherapy.

Prognostic impact of FLT3-ITD microclones in young adults with acute myeloid leukemia treated with intensive chemotherapy.

Journal: Blood

Published: January 20, 2026

Infectious events in fit patients with relapsed or refractory acute myeloid leukemia treated with azacitidine-venetoclax or intensive chemotherapy.

Infectious events in fit patients with relapsed or refractory acute myeloid leukemia treated with azacitidine-venetoclax or intensive chemotherapy.

Journal: International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases

Published: November 19, 2025

Intensive Chemotherapy With or Without Midostaurin in Adults ≥ 60 Years Old With FLT3-Mutated AML: A FILO-DATAML-PETHEMA Real-World Study.

Intensive Chemotherapy With or Without Midostaurin in Adults ≥ 60 Years Old With FLT3-Mutated AML: A FILO-DATAML-PETHEMA Real-World Study.

Journal: American journal of hematology

Published: October 17, 2025

Ziftomenib in Relapsed or Refractory NPM1-Mutated AML.

Ziftomenib in Relapsed or Refractory NPM1-Mutated AML.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: September 25, 2025

Genetic alterations and measurable residual disease in core binding factor acute myeloid leukemia.

Genetic alterations and measurable residual disease in core binding factor acute myeloid leukemia.

Journal: Leukemia

Published: August 25, 2025

Arsenic Trioxide and All-Trans Retinoic Acid Combination Therapy for the Treatment of High-Risk Acute Promyelocytic Leukemia: Results From the APOLLO Trial.

Arsenic Trioxide and All-Trans Retinoic Acid Combination Therapy for the Treatment of High-Risk Acute Promyelocytic Leukemia: Results From the APOLLO Trial.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: August 18, 2025

Functional recovery of NK cells after T-cell replete haploidentical HSCT: delayed licensing and poor anti-acute myeloid leukemia activity.

Functional recovery of NK cells after T-cell replete haploidentical HSCT: delayed licensing and poor anti-acute myeloid leukemia activity.

Journal: Blood advances

Published: July 08, 2025

Showing 1-12 of 148

Last Updated: 09/26/2026